الفهرس 
The role of hdroxycarbamide in long term management of thalassemia intermedia patients / |cEsraa Abdelkader Elhosieny
Abstract EnglishOnly 14 pages are availabe for public view
 |  | from | 175 |  |  |
| | | from | 175 | | |
Abstract
In thalassemia intermedia, there is incomplete inhibition of beta globin protein production. Hydroxyurea increases level of gamma globin and may be effective in these patients.This study was done to evaluate the effect of hydroxyurea in clinical and laboratory profile of these patients. Most of TI patients were female (95.6%), with prevalence of disease related complications about 91.1%. hydroxyurea was well tolerated in 66.6% of patients, and 11.1% had side effects in the form of neutropenia, and elevated liver enzymes. Frequency of blood transfusion was significantly decreased after use of HU. Hb, MCV, MCH, HbF and bleeding profile showed significant increase after HU.There was statistically significant decrease of serum Ferritin, direct bilirubin after HU treatment